Company intelligence / Profile preview

Psychedelic Science Institute

Santa Monica, California, United States

Ownership: Private
Development stage: Other

Overview

Psychedelic Science Institute and its TRIP Clinics have completed or are enrolling in ten clinical trials evaluating psychedelic compounds including psilocybin, LSD, MDMA, and 5-MeO-DMT, primarily for depression, anxiety, PTSD, and alcohol use disorder. Over 10,000 ketamine-assisted psychotherapy sessions have been delivered, with initial data supporting safety and effectiveness for treatment-resistant conditions[5][3][7].

Therapeutic areas: NeurologyPsychiatry
Modalities: Small moleculePsychedelic compoundsKetamine-assisted psychotherapyPsychedelic-assisted psychotherapy
Industry: Biotech

Partnerships

Pacific Neuroscience InstituteCalifornia Center for Psychedelic TherapyIndustry sponsors (not individually named)Academic partners (not individually named)

Beyond the preview

Go deeper on Psychedelic Science Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psychedelic Science Institute.

Explore the full profile